Skip to main content
ABBOTT LABORATORIES logo

ABBOTT LABORATORIES — Investor Relations & Filings

Ticker · ABT ISIN · US0028241000 LEI · HQD377W2YR662HK5JX27 US Manufacturing
Open in API
Filings indexed 4,257 across all filing types
Latest filing 2026-06-18 Annual Report
Country US United States of America
Listing US ABT

About ABBOTT LABORATORIES

https://www.abbott.com

Abbott Laboratories is a global healthcare company that discovers, develops, manufactures, and sells a broad portfolio of life-changing technologies. The company's operations are focused on four core businesses: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. The Medical Devices division offers solutions for cardiovascular health, diabetes care (including the FreeStyle Libre continuous glucose monitoring system), and neuromodulation. The Diagnostics segment provides a wide range of in vitro diagnostic systems and tests for hospitals, laboratories, and clinics. The Nutrition business develops and markets science-based nutritional products for people of all ages, with leading brands such as Similac, PediaSure, Ensure, and Glucerna. The Established Pharmaceuticals division provides a portfolio of branded generic medicines to consumers in emerging markets.

Recent filings

Filing Released Lang Actions
11-K
Annual Report Classification · 95% confidence The document is a SEC Form 11-K, which is an annual report specifically required for employee stock purchase, savings, and similar plans under the Securities Exchange Act of 1934. The document includes extensive financial statements, notes, and an independent auditor's report, indicating it is a comprehensive report covering the plan's financials for the fiscal year ended December 31, 2025. Form 11-K filings are specialized annual reports distinct from the traditional corporate 10-K annual reports but serve a similar purpose of comprehensive annual disclosure. Given the nature of the document—an employee stock plan annual report with audited financial statements—this aligns most closely with the category Annual Report (10-K), which includes official yearly reports covering company activity and full financial performance, as Form 11-K is analogous in its reporting function for employee benefit plans. FY 2025
2026-06-18 English
FORM SD
Regulatory Filings Classification · 92% confidence The document is a Form SD (Specialized Disclosure Report) filed under SEC Rule 13p-1 regarding conflict minerals. It is a standalone regulatory compliance filing, not an annual report, earnings release, or other specific category. There is no category for Form SD or conflict minerals, so it falls under the fallback “Regulatory Filings” category (RNS).
2026-05-27 English
Major Shareholding Notification 2026
Major Shareholding Notification
2026-04-29 English
10-Q
Interim / Quarterly Report
2026-04-29 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC by Abbott Laboratories on April 24, 2026. It reports the election of a new director to the board, adoption of a new stock incentive program, amendments to the bylaws regarding board composition, and shareholder voting results from the Annual Meeting. The key elements involve board member appointment and governance changes. There is also detailed voting results for director elections, executive compensation advisory votes, and approval of stock plans. These disclosures align with announcements about board and management changes and shareholder voting results rather than full annual or interim financial reports. The document is not a full Annual Report (10-K), Interim Report (IR), or Earnings Release (ER), nor is it primarily a proxy statement or voting results document. Instead, it is primarily reporting changes to the Board of Directors and related governance items along with voting results summary. Therefore, the most appropriate classification based on the content is "Board/Management Information (MANG)" since it includes appointment of a new director and amendments to bylaws concerning board size. The inclusion of voting results further supports that this is a governance and management update rather than a financial report. Confidence is high given the clear correspondence to the definition of MANG and typical 8-K usage for such announcements.
2026-04-27 English
S-8 - ABBOTT LABORATORIES (0000001800) (Filer)
Regulatory Filings
2026-04-24 English

Browse filings by year

33 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.